



apoquel
chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)

Apoquel: First Choice for Fast Relief

- ✓ **Fast-acting:**
Proven to start working in as little as 4 hours.^{1,2*} 96% of veterinarians are satisfied with Apoquel efficacy^{3†}
- ✓ **Trusted brand:**
Apoquel brand has been trusted to treat more than 15 million dogs for over a decade, making it the #1 veterinarian-recommended oral treatment for allergic itch relief^{5‡}
- ✓ **Pet-owner preferred[§]:**
Apoquel Chewable is the first and only treat-like chewable for relief of allergic itch; 65% of owners have challenges administering conventional tablet-based therapies to their dog⁶

- ✓ **Proven safety:**
Backed by decade-long pharmacovigilance data: 90% of veterinarians surveyed were satisfied with Apoquel safety^{3†,4}
- ✓ **Easy to use:**
Can be safely used without the burden of checking vaccine status, and long-term without the need to discontinue at the time of any vaccinations
- ✓ **Strengthen pet and owner bond:**
Improved pilling compliance: In a study, 91.6% of Apoquel Chewable doses were accepted voluntarily⁷

Apoquel takes the lead in a side-by-side comparison allowing for uninterrupted dosing with vaccination

	apoquel (oclacitinib tablet)	apoquel chewable (oclacitinib chewable tablet)	Zenrelia ⁸ (ilunocitinib tablets)
Boxed WARNING on label	No	No	Yes See Boxed WARNING on reverse side
Can be used before, after, and at the time of ANY vaccination	✓	✓	✗ ^{††}
Adequate immune response to rabies vaccine with concurrent use	✓	Apoquel Chewable and Apoquel tablet are expected to have comparable safety ^{9,10}	✗ [#]
Can be used concomitantly with ANY vaccines^{††}	✓	✓	✗
Mechanism of action	JAK1,3 selective ¹²	JAK1,3 selective	Non-selective JAK inhibitor ¹³
Starts to control allergic itch in 4 hours^{1,2*}	✓	✓	✗
Significant improvement in allergic itch in 24 hours¹⁴	✓	✓	Visible improvement in allergic itch from day 1
Continuous, uninterrupted dosing regimen	✓	✓	Maintenance dosing interrupted (28 days-3 months pre-vaccination and 28 days post-vaccination)
Manage flares with 1-14 days BID dosing	✓	✓	✗
Chewable formulation preferred by pet owners^{6§}	✗	✓	✗



apoquel[®]
chewable
(oclacitinib chewable tablet)

apoquel[®]
(oclacitinib tablet)

*Data for Apoquel Chewable is based on a model study for canine flea allergic dermatitis.
†Based on a survey of DVMs, n=744.
‡Apoquel tablet launched January 2014; Apoquel Chewable launched October 2023.
§Responses based on owner review of Apoquel tablet and Apoquel Chewable product profiles in a survey.
¶Discontinue Zenrelia for at least 28 days to 3 months before any vaccination and withhold Zenrelia for at least 28 days after vaccination.
#Dogs are at risk of inadequate immune response to any vaccine with concurrent use.

Zenrelia Boxed WARNING⁸
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live-virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.

APOQUEL AND APOQUEL CHEWABLE IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines. See full Prescribing Information at [ApoquelTabletAndChewablePI.com](https://www.zoetis.com/ApoquelTabletAndChewablePI.com).

Apoquel and Apoquel Chewable Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

References: **1.** Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel[®]) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. *Vet Dermatol.* 2014;25(6):512-e86. **2.** Data on File, Study Report No. A162R-US-21-C32, 2022, Zoetis Inc. **3.** Data on File, Apoquel/Cytopoint Vet Tracker Wave 18, 2024; Zoetis Inc. **4.** Data on file. A Ten-Year Post-Approval Safety Review for APOQUEL[®] in the US (May 2013 to August 2023), Zoetis Inc. **5.** Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel: January 2014 – February 2024. **6.** Data on File, ZMR: Adelphi/PROVE: Pet Owner Preferences Chewable Vs. Conventional Canine Pruritus, Zoetis Services LLC, March 2023. **7.** Visser M, Walsh K, King V, et al. Acceptance of oclacitinib maleate (Apoquel[®]) chewable tablets in client-owned dogs with allergic and atopic dermatitis. *BMC Vet Res.* 2022;18(1):103. **8.** Zenrelia Prescribing Information. Elanco US Inc. Greenfield, IN. 2024. **9.** Data on file: Study Report A461N-US-21-B66, 2022, Zoetis Inc. **10.** FOI Apoquel Chewable FOI Summary: 2023/06/09 Original NADA 141-555 (v2.0). **11.** Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. *Vet Dermatol.* 2015;26(3):171-179. **12.** Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL[®]) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. *J Vet Pharmacol Ther.* 2014;37(4):317-324. **13.** US Zenrelia[®] tablet FOI. **14.** Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. *Vet Dermatol.* 2013;24(5):479-e114.

Zenrelia is a trademark of Elanco US Inc.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2025 Zoetis Services LLC. All rights reserved. APC-00249R1

